SCHEMBL23217922

SCHEMBL23217922

NCCc1cnc2ccc(-c3c(-c4cccc(C(F)(F)F)n4)nn4c3CCC4)cc2n1

nearest known ligand 0.60

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 19/20 0.60
THRB P10828 7/20 0.60
TGFBR2 P37173 7/20 0.46
MAP3K20 Q9NYL2 5/20 0.46
CYP2D6 P10635 1/20 0.46
MAPK14 Q16539 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24312356 0.87 TGFBR1 (0.62) TGFBR1THRBTGFBR2MAP3K20CYP2D6
SCHEMBL24312016 0.87 TGFBR1 (0.58) TGFBR1THRBTGFBR2MAP3K20CYP2D6
SCHEMBL23217901 0.87 TGFBR1 (0.54) TGFBR1THRBTGFBR2MAP3K20CYP2D6
SCHEMBL24312017 0.87 TGFBR1 (0.60) TGFBR1THRBTGFBR2MAP3K20CYP2D6
SCHEMBL24312440 0.85 TGFBR1 (0.56) TGFBR1THRBTGFBR2MAP3K20CYP2D6
SCHEMBL24311955 0.85 TGFBR1 (0.58) TGFBR1THRBTGFBR2MAP3K20CYP2D6
SCHEMBL24311922 0.81 TGFBR1 (0.48) TGFBR1THRBTGFBR2MAP3K20CYP2D6
SCHEMBL24312353 0.80 TGFBR1 (0.64) TGFBR1THRBTGFBR2MAP3K20CYP2D6
SCHEMBL24312018 0.78 TGFBR1 (0.53) TGFBR1THRBTGFBR2MAP3K20CYP2D6
SCHEMBL412382 0.76 TGFBR1 (1.00) TGFBR1THRBTGFBR2MAP3K20CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076905-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed
WO-2021072330-A1 GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES SILVERBACK THERAPEUTICS, INC. (US) 2021-04-15 WO disclosed
WO-2021072330-A1 GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES SILVERBACK THERAPEUTICS, INC. (US) 2021-04-15 WO disclosed